B. Lowe

Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial

R. Hayes, S. Kapiga, D. Watson-Jones, 2022, The Lancet. Global health.

A Hierarchy of norms Defined via Blackwell Games

B. Lowe, 2003 .

Prevalence of malaria and helminth infections in rural communities in northern Sierra Leone, a baseline study to inform Ebola vaccine study protocols

D. Watson-Jones, D. Ishola, M. Hodges, 2022, PloS one.

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

S. Lees, D. Watson-Jones, M. Belson, 2020, Trials.

Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone

D. Watson-Jones, D. Ishola, E. Smout, 2022, Emerging infectious diseases.

Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children

D. Watson-Jones, Pauline Akoo, D. Ishola, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.

D. Watson-Jones, C. McLean, G. Deen, 2022, The Lancet. Infectious diseases.

Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study

D. Watson-Jones, K. Tetteh, K. Kasonia, 2023, International Journal of Infectious Diseases.

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen

D. Watson-Jones, C. Drakeley, S. Soremekun, 2023, Vaccines.

Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study

K. Tetteh, K. Kasonia, B. Lawal, 2023 .

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.

D. Watson-Jones, E. D’Ortenzio, D. Ishola, 2023, The Lancet. Global health.

Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.

D. Watson-Jones, P. Kaleebu, O. Anzala, 2023, Vaccine.